Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9646)	4/15/1999 9:00:00 PM
From: aknahow	Respond to of 17367

And I agree with every point you made. In spite of anything I have said in the past, with the exception fo floorless financing other than with GNE, I think management at XOMA has done an excellent job. The IDPH deal was inventive and necessary, even though with hindsight it would have been interesting to be collecting royalties. The Bermuda move, also smart. Gene expression deals. The patent deals and the patents themselves. And of course participation in three P III trials. When one thinks of all the junk that has skyrocketed on nothing it is easy to remain enthused about XOMA, even with its' terrible market performance.